SEHK:489
SEHK:489Auto

The Bull Case For Dongfeng Motor Group (SEHK:489) Could Change Following Renewed VOYAH Spin-off Focus - Learn Why

Recent coverage highlighted that Dongfeng Motor Group continues to own 100% of Hong Kong-based EV subsidiary VOYAH, as investors revisit its potential spin-off amid active spin-off interest in the Hong Kong market. The discussion of VOYAH’s standalone valuation, competitive position in China’s crowded EV sector, and Hong Kong listing rules offers fresh insight into how a spin-off could reshape Dongfeng’s business profile. We will now examine how the renewed focus on a possible VOYAH spin-off...
SEHK:3933
SEHK:3933Pharmaceuticals

The Bull Case For United Laboratories International Holdings (SEHK:3933) Could Change Following Key Cefoperazone-Sulbactam Approval

United Laboratories International Holdings recently reported that its wholly owned Zhongshan branch of Zhuhai United Laboratories received China National Medical Products Administration approval, with quality and efficacy consistency evaluation, for its 2.0g Cefoperazone Sodium and Sulbactam Sodium for Injection, already classified as a Category B drug in the 2024 National Medical Insurance Drug List. This outcome strengthens the company’s anti-infective portfolio by validating a...
SEHK:290
SEHK:290Capital Markets

GoFintech Quantum Innovation (SEHK:290): Valuation Check After Swinging From Loss to Half-Year Profit

GoFintech Quantum Innovation (SEHK:290) just flipped its half year results from a small loss to a net profit, and that earnings swing is quickly becoming the main story behind the stock’s recent momentum. See our latest analysis for GoFintech Quantum Innovation. That earnings swing helps explain why the share price has climbed to HK$2.29, with a powerful year to date share price return of 186.25% and a remarkable three year total shareholder return of 1,599.01%, suggesting momentum is still...
SEHK:1810
SEHK:1810Tech

Xiaomi (SEHK:1810) Valuation Check After Record Q3 and 199% Smart EV Revenue Surge

Xiaomi (SEHK:1810) just posted a standout third quarter, with several metrics hitting record highs and its Cars unit delivering a breakthrough as smart electric vehicle and innovation revenue surged more than 199% year over year. See our latest analysis for Xiaomi. The upbeat quarter has helped Xiaomi regain some investor confidence, with the latest HK$42.78 share price sitting against a solid year to date share price return. A powerful three year total shareholder return above 270% suggests...
SEHK:17
SEHK:17Real Estate

New World Development (SEHK:17): Reassessing Valuation After Major Debt Exchange and Sharp Balance Sheet Deleveraging

New World Development (SEHK:17) has just wrapped up a major debt exchange, issuing about USD 1.36 billion in new bonds and cutting its debt load by nearly 50%, a meaningful shift for equity holders. See our latest analysis for New World Development. The sizeable debt cut seems to have given sentiment a lift, with a 1 day share price return of 4.87% helping extend its year to date share price return of 41.07%. However, the 3 year total shareholder return is still deeply negative at 62.10%. If...
SEHK:2245
SEHK:2245Metals and Mining

Lygend Resources & Technology (SEHK:2245) Valuation Check as Investors Weigh Extraordinary General Meeting on Related-Party Deals

Lygend Resources & Technology (SEHK:2245) has called an Extraordinary General Meeting for December 19, 2025, to seek approval for related party transactions, a move that puts governance and transparency squarely in focus for shareholders. See our latest analysis for Lygend Resources & Technology. The governance spotlight from this Extraordinary General Meeting comes after a sharp run up, with the 188.52% year to date share price return and 147.95% one year total shareholder return suggesting...
SEHK:1093
SEHK:1093Pharmaceuticals

CSPC Pharmaceutical Group (SEHK:1093) Valuation After Dual China–US Trial Approvals for Obesity and Kidney Drug Candidates

CSPC Pharmaceutical Group (SEHK:1093) just cleared two regulatory hurdles, securing trial approvals in China and the US for first in class obesity and kidney disease candidates, giving investors fresh, data-driven reasons to revisit the stock. See our latest analysis for CSPC Pharmaceutical Group. These back to back trial greenlights land at a time when CSPC Pharmaceutical Group’s 1 year total shareholder return of 58.59 percent contrasts sharply with a weak 90 day share price return of...
SEHK:1133
SEHK:1133Electrical

Harbin Electric (SEHK:1133) Valuation Check After HSBC’s Bullish Call on Its Clean Power Role

HSBC Global Research has just spotlighted Harbin Electric (SEHK:1133), highlighting its role in nuclear and hydropower supply as China wrestles with energy oversupply and fast rising demand from AI driven data centers. See our latest analysis for Harbin Electric. The HSBC call lands on a stock that has already been on a tear, with a roughly 66% 3 month share price return and a near fivefold 1 year total shareholder return, suggesting momentum is still very much intact despite only modest...
SEHK:2602
SEHK:2602Real Estate

Assessing Onewo (SEHK:2602)’s Valuation After Launching a 10% H-Share Buyback Program

Onewo (SEHK:2602) just put a clear marker down by kicking off a buyback of up to 10% of its H shares, signaling confidence in its long term outlook and capital discipline. See our latest analysis for Onewo. The buyback news lands after a choppy stretch, with a 30 day share price return of minus 11.07% and a three year total shareholder return of minus 55.31%. Management is clearly trying to reset sentiment and rebuild momentum. If this kind of opportunistic capital return has you thinking...
SEHK:6855
SEHK:6855Biotechs

Revisiting Ascentage Pharma Group International (SEHK:6855)’s Valuation After Its Strong One-Year Share Price Gain

Ascentage Pharma Group International (SEHK:6855) has quietly outperformed over the past year, and with shares up roughly 56% in that time, investors are starting to revisit the story behind this clinical stage biotech. See our latest analysis for Ascentage Pharma Group International. The stock has been choppy in recent months, with a 1 day share price return of 4.44 percent and a 90 day share price return of minus 19.91 percent. However, a 1 year total shareholder return of 55.76 percent...
SEHK:1672
SEHK:1672Biotechs

Is Ascletis Pharma (SEHK:1672) Quietly Reframing Its Obesity Strategy With ASC37’s Oral Triple Agonist?

In late November 2025, Ascletis Pharma announced it had selected ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist developed with its POTENT and AI-assisted technologies, as a clinical development candidate and outlined plans to file a US FDA Investigational New Drug application for obesity treatment in 2026. The company highlighted that ASC37 showed much higher in vitro potency and substantially improved oral bioavailability versus existing incretin drugs in non-human primate studies,...
SEHK:386
SEHK:386Oil and Gas

What China Petroleum & Chemical (SEHK:386)'s DME Marine Fuel Push Means For Shareholders

Earlier this month, a coalition of major Chinese state-owned enterprises and academic institutions, including China Petroleum & Chemical Corp. (Sinopec), launched an initiative to promote dimethyl ether (DME) as a cleaner and safer next-generation marine fuel, targeting advances in production, engine systems, refueling infrastructure, and safety standards. This alliance positions Sinopec at the center of efforts to accelerate low-emission shipping fuels, potentially reinforcing its role in...
SEHK:2233
SEHK:2233Basic Materials

What West China Cement (SEHK:2233)'s 2026 Bond Tender Completion Reveals About Its Balance Sheet

West China Cement has completed the settlement of its tender offer for the 2026 notes, leaving US$200 million in aggregate principal outstanding, clarifying its current debt position. This adjustment to the bond balance offers investors greater transparency on the company’s capital structure and ongoing balance sheet management efforts. Next, we will examine how this refined debt profile, particularly the remaining US$200 million of 2026 notes, shapes West China Cement’s investment...
SEHK:3618
SEHK:3618Banks

Does Issuing RMB1 Billion Sci-tech Bonds Recast Chongqing Rural Commercial Bank’s (SEHK:3618) Innovation Strategy?

Chongqing Rural Commercial Bank has recently completed the issuance of RMB1 billion sci-tech innovation bonds in the national inter-bank bond market to channel funding into technology-focused enterprises. This bond issue underlines the bank’s growing role as a financial conduit for China’s innovation agenda, aligning its balance sheet more closely with sci-tech lending and investment. We’ll now examine how this sci-tech bond issuance shapes Chongqing Rural Commercial Bank’s investment...